Vigabatrin: Phase II started

Catalyst said investigators at the Mount Sinai School of Medicine began an open-label, U.S.

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE